# Molecular mechanisms of metabolic rewiring in cancer cells and therapeutic implications.

**Walker Axe***

Department of Cell Biology and Institute of Biomembranes, University Medical Centre Utrecht, Heidelberglaan Utrecht, Netherlands

## Introduction

Metabolic rewiring is a hallmark feature of cancer cells, characterized by altered metabolic pathways that support their rapid proliferation and survival. Cancer cells undergo significant changes in their metabolism to meet the demands of increased biomass production, energy generation, and redox balance. This article aims to explore the molecular mechanisms underlying metabolic rewiring in cancer cells and discuss the therapeutic implications of targeting these alterations.

### *Warburg effect and aerobic glycolysis*

One of the most prominent metabolic alterations in cancer cells is the preference for aerobic glycolysis, known as the Warburg effect. Unlike normal cells, which predominantly generate ATP through oxidative phosphorylation, cancer cells exhibit increased glucose uptake and fermentation of glucose into lactate, even in the presence of oxygen. This metabolic shift allows cancer cells to rapidly produce ATP and divert glucose intermediates into biosynthetic pathways for the synthesis of nucleotides, lipids, and amino acids, which are essential for cell proliferation. The Warburg effect is driven by several molecular mechanisms. The activation of oncogenes, such as MYC and HIF-1α, promotes the upregulation of glucose transporters (e.g., GLUT1) and glycolytic enzymes. Additionally, mutations in key metabolic enzymes, such as pyruvate kinase M2 (PKM2) and isocitrate dehydrogenase (IDH), contribute to the metabolic rewiring observed in cancer cells. PKM2 isoform, which is predominantly expressed in cancer cells, has reduced enzymatic activity, leading to the accumulation of glycolytic intermediates that support biosynthesis [1].

### *Altered amino acid metabolism*

In addition to glucose metabolism, cancer cells also exhibit changes in amino acid metabolism to sustain their rapid growth and proliferation. Amino acids serve as building blocks for protein synthesis and provide a source of energy and intermediates for various metabolic pathways. Cancer cells often upregulate amino acid transporters to increase the uptake of essential amino acids from the extracellular environment. One notable alteration in amino acid metabolism is the increased dependency on glutamine. Glutamine is a non-essential amino acid that serves as a carbon and nitrogen donor for nucleotide and amino acid synthesis. Cancer cells enhance glutamine uptake and utilize it for the replenishment of the tricarboxylic acid (TCA) cycle intermediates, a process known as anaplerosis. Glutamine also contributes to the maintenance of redox balance and supports the synthesis of antioxidants, such as glutathione, which protects cancer cells from oxidative stress [2].

### *Lipid metabolism and lipogenesis*

Cancer cells exhibit enhanced lipid metabolism to support their high demand for membrane synthesis and energy storage. They unregulated fatty acid synthesis pathways, leading to increased de novo lipogenesis. This process involves the conversion of glucose-derived carbon into fatty acids, which are subsequently used for the synthesis of phospholipids and triacylglycerols. The master regulator of lipogenesis in cancer cells is sterol regulatory element-binding protein (SREBP). SREBP promotes the expression of enzymes involved in fatty acid synthesis, such as acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN). Additionally, oncogenic signaling pathways, such as PI3K/AKT/mTOR, activate SREBP and enhance lipogenesis in cancer cells. Targeting lipogenesis pathways has emerged as a potential therapeutic strategy to disrupt cancer cell proliferation and survival [3].

### *Mitochondrial metabolism and oxidative stress*

Mitochondria play a crucial role in cellular metabolism by generating ATP through oxidative phosphorylation and contributing to various biosynthetic pathways. In cancer cells, mitochondrial metabolism undergoes significant alterations. While some cancers exhibit increased mitochondrial activity, others display mitochondrial dysfunction and rely heavily on glycolysis for energy production. Mitochondrial dysfunction in cancer cells leads to the accumulation of reactive oxygen species (ROS) and oxidative stress. ROS can promote genomic instability, signaling pathway activation, and metabolic adaptation in cancer cells. To counteract oxidative stress, cancer cells upregulate antioxidant defense systems, including the synthesis of antioxidants and activation of antioxidant enzymes [4].

### *Therapeutic implications*

Understanding the molecular mechanisms of metabolic rewiring in cancer cells has significant therapeutic implications.

***Correspondence to:** Walker Axe, Department of Cell Biology and Institute of Biomembranes, University Medical Centre Utrecht, Heidelberglaan Utrecht, Netherlands. E-mail: walker_axe5824@hotmail.com

***Received:** 19-May-2023, Manuscript No. AACBM-23-101825; **Editor assigned:** 23-May-2023, PreQC No. AACBM-23-101825(PQ); **Reviewed:** 06-Jun-2023, QC No AACBM-23-101825; **Revised:** 12-Jun-2023, Manuscript No. AACBM-23-101825(R); **Published:** 19-Jun-2023, DOI:10.35841/aacbm-5.3.151*

***Citation:** Axe W. Molecular mechanisms of metabolic rewiring in cancer cells and therapeutic implications. J Cell Biol Metab. 2023;5(3):151*

Targeting cancer metabolism has emerged as a promising strategy to selectively kill cancer cells while sparing normal cells. Several approaches have been explored, including inhibiting glycolysis, blocking amino acid transporters, and targeting lipogenesis. Inhibitors of glycolysis, such as 2-deoxyglucose (2-DG) and lonidamine, have shown promising results in preclinical studies and clinical trials. These compounds interfere with glycolytic enzymes or glucose transporters, leading to reduced ATP production and impaired biosynthesis in cancer cells. Moreover, targeting glutamine metabolism, either by inhibiting glutamine transporters or enzymes involved in glutamine utilization, has demonstrated efficacy in preclinical models. Targeting lipogenesis pathways, such as FASN inhibitors, has shown promise in preclinical studies, particularly in cancers with high lipogenic activity. These inhibitors disrupt lipid synthesis and induce metabolic stress, leading to impaired cancer cell growth. Furthermore, therapeutic strategies aimed at inducing mitochondrial dysfunction or targeting mitochondrial metabolism in cancer cells is being explored [5].

## Conclusion

Metabolic rewiring is a hallmark feature of cancer cells, enabling their rapid proliferation and survival. Alterations in glucose metabolism, amino acid metabolism, lipid metabolism, and mitochondrial function contribute to the metabolic phenotype of cancer cells. Understanding the underlying molecular mechanisms provides insights into potential therapeutic targets for cancer treatment. Targeting cancer metabolism represents a promising approach for the development of novel anticancer therapies and combination treatments to improve patient outcomes. Further research is needed to unravel the complex metabolic networks in cancer cells and optimize therapeutic strategies for clinical applications.

## References


1. Cacace A, Sboarina M, Vazeille T, et al. Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism. Oncogene. 2016;36:2074-84.
2. Jewell JL, Kim YC, Russell RC, et al. Differential regulation of mTORC1 by leucine and glutamine. Science. 2015;347:194-8.
3. Zhang J, Pavlova NN, Thompson CB. Cancer cell metabolism: The essential role of the nonessential amino acid, glutamine. EMBO J. 2017;36:1302-15.
4. Mates JM, Campos-Sandoval JA, Santos-Jimenez JDL, et al. Dysregulation of glutaminase and glutamine synthetase in cancer. Cancer Lett. 2019;467:29-39.
5. Mates JM, Segura JA, Martin-Rufian M, et al. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr Mol Med. 2013;13:514-34.



***Citation:*** *Axe W. Molecular mechanisms of metabolic rewiring in cancer cells and therapeutic implications. J Cell Biol Metab. 2023;5(3):151*